Trial Search Results

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Vincristine
  • Drug: Cyclophosphamide
  • Drug: Doxorubicin
  • Drug: Prednisone
  • Drug: Bleomycin
  • Drug: Etoposide
  • Radiation: Low-dose radiotherapy (RT)

Phase:

Phase 2

Eligibility


INCLUSION CRITERIA:

   - Diagnosis of previously untreated stage I or IIA Hodgkin's lymphoma, eligible subtypes

      - Nodular sclerosis

      - Mixed cellularity

      - Classical, not otherwise specified

   - Age ≥ 18 years and ≤ 70 years

   - Granulocytes ≥ 2 x 10e6/µL

   - Platelets ≥ 150 x 10e6/µL

   - Bilirubin ≤ 2.5 mg/dL

   - Serum creatinine ≤ 2 mg/dL

   - Patients > 50 years or those with a history of cardiac disease should have an ejection
   fraction ≥ 50%

   - All scans, X-rays, laboratory tests must be performed within 6 weeks of enrollment

   - Pathologic material reviewed at Stanford University

   - Evaluation by Stanford Medical Oncology and Radiation Oncology with review at the
   Hodgkin's Disease Staging Conference

   - Written informed consent

EXCLUSION CRITERIA:

   - Lymphocytic predominance Hodgkin's disease

   - Prior treatment for Hodgkin's disease

   - Mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter
   on a standing posteroanterior chest x-ray

   - Any lymph node mass > 10 cm in greatest trans-axial diameter

   - Two or more extranodal sites of disease

   - Constitutional (B) symptoms present at diagnosis

   - Prior or concurrent malignancies within 5 years (EXCEPTION: basal cell carcinoma of
   the skin)

   - Any medical contraindication to the planned treatment, including:

      - Pregnant

      - Positive antibody test for the human immunodeficiency virus (HIV)

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Anne Wiley
6507256432
Not Recruiting